911398-13-5

BIIB-028 is an orally active inhibitor for heat shock protein 90 (Hsp90). BIIB-028 targets the ATP-binding site of Hsp90, disrupts the function of Hsp90, leads to the degradation of client proteins, that are crucial for cancer cell survival and proliferation[1][2].

[1] Soga S, et al., Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des. 2013;19(3):366-76. DOI:10.2174/138161213804143617
[2] Rahimi M N. Investigating cyclic peptide inhibitors of heat shock protein 90 (Hsp90): from design and synthesis to cellular drug delivery[D]. UNSW Sydney, 2020.